Hartnup Disease


Practice Essentials

Hartnup disease is an autosomal recessive disorder caused by impaired neutral (ie, monoaminomonocarboxylic) amino acid transport in the apical brush border membrane of the small intestine and the proximal tubule of the kidney. Patients present with pellagralike skin eruptions, cerebellar ataxia, and gross aminoaciduria.[1, 2, 3, 4]



In 1956, Baron et al described the disorder in the Hartnup family of London; 4 of the 8 family members presented with aminoaciduria, a rash resembling pellagra, and cerebellar ataxia.[1]

Hartnup disease is inherited as an autosomal recessive trait. Heterozygotes are normal. Consanguinity is common. In 2004, a causative gene, SLC6A19 (MIM#608893, Genbank accession NM 001003841) , was located on band 5p15.33. SLC6A19 is a sodium-dependent and chloride-independent neutral amino acid transporter, expressed predominately in the kidneys and intestine.[5, 6, 7, 8]


In 2001, homozygosity mapping by Nozaki et al. in consanguineous Japanese pedigrees demonstrated linkage of Hartnup disorder to band 5p15.[8] A gene survey of 5p15 revealed several members of the SLC6 family comprising transporters for neurotransmitters, osmolytes, and amino acids, and linkage analysis in 7 Australian families narrowed the region to 7cM on 5p15.33 containing SLC6A18 and SLC6A19. Cloning and expression of the mouse SLC6A19 gene demonstrated that this transporter has all the properties of the amino acid transport system B0 AT1[9, 10] . In an animal model of Hartnup disorder, mice lacking SLC6A19 (B0 AT1) transporter general neutral aminoaciduria were observed, as well as the decreased body weight, demonstrating the essential role of epithelial amino acid uptake in optimal growth and bodyweight regulation.[11]

The human SLC6A19 gene was cloned independently by 2 groups of researchers in 2004.[6, 12] It has the same transporter properties and expression pattern as the mouse transporter. Both studies demonstrated that mutations in SLC6A19 are associated with Hartnup disorder. The requirement for 2 transport-impairing mutations for disease expression confirmed a recessive mode of inheritance[5, 6] .

Currently, 17 mutations in SLC6A19 have been described in patients with Hartnup disorder. In all investigated individuals with Hartnup disorder, 2 mutant SLC6A19 alleles were found, confirming recessive mode of inheritance. Reanalysis of families in whom mutations in SLC6A19 were not found in the first study revealed the existence of mutations in different allelles.[5, 6, 13] Thus, in all families studied to date, allelic heterogeneity at SLC6A19 has been found, without the evidence for genetic heterogeneity of the disorder.[13] The most common mutation in Hartnup disorder is c.517G→A, resulting in the amino acid substitution p.D173N, and it can be found in 43% of patients.[13] .

A novel mutation, c.850G→A, in exon 6 of the SLC6A19 gene was described in a Chinese family with typical clinical characteristics of Hartnup disorder.[14] Also, a mutation in the SLC6A19 gene was described in a 6-year-old patient with late-onset seizures in whom pellagralike skin lesions developed after the diagnosis of Hartnup disease at age 9 years, confirming the allelic, as well as phenotypic, heterogeneity of the disease.[15]

Investigation of the origins of the D173N allele revealed an allele frequency estimate in the population of 0.004 and a heterozygote frequency of 1 in 122 healthy individuals of European descent. A single core haplotype surrounding the D173N alleles was found, which suggests that the mutation is identical by descent in all observed cases; therefore, it is not a result of a recurrent mutation.[16] Estimates of the allele age indicate that this allele arose more than 1000 years ago.[16]

Mutations in the SLC6A19 gene, which encodes the SLC6A19 (B0 AT1) neutral amino acid transporter, causes a failure of the transport of neutral (ie, monoaminomonocarboxylic) amino acids in the small intestine and the renal tubules.[2, 4, 17] The B0 AT1 transporter is a sodium-dependent, chloride-independent system and transports all neutral amino acids in the following order: Leu=Val=Ile=Met –> Gln=Phe=Ala=Ser=Cys=Thr –> His=Trp=Tyr=Pro=Gly.[2, 18] B0 AT1 appears to be largely restricted to the kidneys and intestine; however, expressed sequence tags have been reported in skin.[17, 18] .

SLC6A19 (B0 AT1) expression and function is controlled by the brush-border angiotensin-converting enzyme 2 (ACE2), as well as the serum and glucocorticoid inducible kinases SGK1-3, which were shown recently to be potent stimulators of SLC6A19.[19] Other mechanisms of SLC6A19 regulation are unknown. In patients with Hartnup disease and in cystinuria, intestinal peptid transporter (PEPT1) appears to be essential to compensate for the reduced amino acid delivery through intestinal epithelium.[20]

Although tryptophan is transported by this transporter rather inefficiently, it is thought to be one of the key substrates in the development of the nonrenal symptoms of Hartnup disorder. Tryptophan is converted in the liver to niacin, and approximately half of the nicotinamide adenine dinucleotide phosphate (NADPH) synthesis in humans is generated through tryptophan. As a result, tryptophan and niacin deficiencies generate similar symptoms. In addition, symptoms in persons with Hartnup disorder quickly respond to nicotinic acid supplementation.[2, 4, 17, 18]

Amino acids are retained within the intestinal lumen, where they are converted by bacteria to indolic compounds that can be toxic to the CNS. Tryptophan is converted to indole in the intestine. Following absorption, indole is converted to 3-hydroxyindole (ie, indoxyl, indican) in the liver, where it is conjugated with potassium sulfate or glucuronic acid. Subsequently, it is transported to the kidneys for excretion (ie, indicanuria). Other tryptophan degradation products, including kynurenine and serotonin, are also excreted in the urine. Tubular renal transport is also defective, contributing to gross aminoaciduria. Neutral amino acids are also found in the feces.[2, 4, 7, 17, 21]

Resorption of the peptides may partially compensate for the lack of amino acid transport in persons with Hartnup disorder, and thus phenotypic variability is wide, which may result from a number of factors: differential resorption, allelic and genetic heterogeneity, modifier genes, and dietary intake.[22, 23] Most patients remain asymptomatic, and it has been suggested that Hartnup phenotype becomes apparent when environmental or genetic factors predispose individuals to a lack of amino acid uptake. Oakley and Wallace reported a case of Hartnup disease in an adult, with the first appearance of symptoms after prolonged lactation and increased physical activity.[24]



United States

Newborn screening programs in Australia and North America have identified an overall incidence of 1 case per 30,000 births; in Massachusetts, it was 1 case per 23,000 births.[25] With an overall prevalence of 1 case per 24,000 population (range, 1 case per 18,000-42,000 population), Hartnup disease ranks among the most common amino acid disorders in humans.[25]


Newborn screening programs in Australia and North America have identified an overall incidence 1 case per 25,000 births in New South Wales and 1 case per 54,000 births in Quebec.[25] The disorder has been reported to occur in all ethnic groups studied to date, including those from Israel, Japan, West Africa, and India.


No racial predilection is recognized for Hartnup disease.[25]


No sexual predilection has been reported for Hartnup disease.[25]


The onset of Hartnup disease is in childhood, usually in children aged 3-9 years, but it may present as early as 10 days after birth. In addition, a case of Hartnup disease presenting for the first time in an adult female, after prolonged lactation and increased physical activity, is described.[3, 24, 25]


Hartnup disease is manifested by a wide clinical spectrum. Most patients remain asymptomatic, but, in a minority of patients, skin photosensitivity and neurologic and psychiatric symptoms may have a considerable influence on quality of life. Rarely, severe CNS involvement may lead to death. Mental retardation and short stature have been described in a few patients. Malnutrition and a low-protein diet are the primary factors that contribute to morbidity.[3, 22, 23, 25, 26]

Attacks become less frequent with increasing age.[23]

Maternal Hartnup disease does not influence the outcome of pregnancy. Placental transport of free amino acids may not be reduced in maternal Hartnup disorder.[27]

Patient Education

Educate patients to protect themselves from sunlight, to avoid other aggravating factors, and to consume a high-protein diet.


Hartnup disease is manifested by a wide clinical spectrum and phenotypic heterogeneity (see Physical for a complete discussion of the clinical signs).[22, 23, 28]

Most children with the Hartnup defect remain asymptomatic.

In Australia, an 8-year follow-up study of 12 patients found only 2 clinical episodes that may be ascribed to Hartnup disease; mental development of all of the children was normal. In the United States, a full-blown picture of the disorder is rarely seen, probably because the diet of US residents is adequate.[23]

Patients who are symptomatic present with episodic deterioration of neurologic and dermatologic manifestations. Symptoms progress over several days and last for 1-4 weeks before spontaneous remission occurs.

Cutaneous signs usually precede the neurologic manifestations, but in rare patients, neurologic manifestations can precede skin changes.[24, 15]

Psychiatric symptoms (eg, anxiety, emotional instability, mood changes) are common in patients who are symptomatic. Psychotic episodes and delirium are rarely seen.

Physical Examination

Skin findings [1, 23, 26]

Photosensitivity occurs (see the image below).The skin reddens after exposure to sunlight (see the image below). Further exposures lead to the development of dry, scaly, well-marginated eruptions, sometimes resembling chronic eczema. This eruption preferentially affects the forehead, the cheeks, the periorbital regions, the dorsal surfaces of the hands, and other light-exposed areas.

View Image

Photosensitivity with erythema, desquamation, and hypopigmentation and hyperpigmentation on the face.

View Image

Erythema and desquamation on the sun-exposed area of the right arm.

Lesions on the face may resemble the malar rash of lupus erythematosus.

A vesiculobullous eruption with exudation may occur.

Skin changes leave long-lasting hypopigmentation and/or hyperpigmentation, which are intensified with further sunlight exposure.

One case with widespread cutaneous eruption resembling acrodermatitis enteropathica was described,[29] as well as a patient with manifestations of kwashiorkor and acrodermatitis enteropathica but with normal zinc levels, which led to the search for other metabolic disorders, and Hartnup disorder was confirmed.[30]

In two patients with celiac disease, Hartnup disease was found in treatment-refractory celiac disease. In both patients, exfoliative erythroderma of malnutrition developed and it resolved after a high-protein and gluten-free diet was instituted.[31, 32]

Central nervous system findings [33]

Mental development is normal in most patients, but mental retardation (intelligence quotient of 50-70) is described in a few patients. Of 1087 patients screened for the detection of inherited metabolic diseases from the Alexandra Institute for persons with mental retardation in Cape Town, Hartnup disease was found in only 1 patient.[34]

Neurologic symptoms may vary and are fully reversible. Intermittent cerebellar ataxia, a wide-based gait, spasticity, delayed motor development, and tremulousness are the most frequent findings. Headaches and hypotonia may also occur.[23, 28, 35] . Late-onset seizures and adult-onset Hartnup disease with neurologic manifestations as the first signs have been described, with pellagralike skin lesions developing after the neurologic symptoms.[24, 15]

Other findings

Ocular manifestations include double vision, nystagmus, photophobia, and strabismus.[28]

Gingivitis, stomatitis, and glossitis suggest niacin deficiency.[3, 33]

Diarrhea occasionally precedes or follows attacks of the disease.[3, 33]

Short stature has been described. Wilcken et al found that of 14 patients with Hartnup disorder who were observed for 8 years, 10 had height percentiles less than the midparent height percentiles, while 4 had percentiles equal to or above the midparent percentiles.[23]


Exacerbations are seen most frequently in the spring or early summer after exposure to sunlight. The attacks may be provoked by a febrile illness, poor nutrition, sulfonamides, and possibly emotional stress and increased physical activity.[24, 25]


Complications are as follows[3, 22, 35] :

Laboratory Studies

With urine chromatography,[3, 21, 22, 25, 28] increased levels of neutral amino acids (eg, glutamine, valine, phenylalanine, leucine, asparagine, citrulline, isoleucine, threonine, alanine, serine, histidine, tyrosine, tryptophan) and indican are found in the urine. Urinary indoxyl derivatives (ie, 5-hydroxyindoleacetic acid) may be demonstrated following an oral tryptophan load. Urine excretion of proline, hydroxyproline, and arginine remains normal, which differentiates Hartnup disease from other causes of gross aminoaciduria. Perform urine chromatography to exclude nutritional pellagra.

Plasma concentrations of amino acids are usually normal.[3, 21, 22, 25, 28]


Jejunal biopsy may be required in selected patients (transport defect may be identified in vitro). Skin biopsy may be required in selected patients.[22, 24, 25, 26]

Histologic Findings

Changes in the skin are similar to those seen in pellagra. Findings are not diagnostic and include hyperkeratosis, parakeratosis, epidermal atrophy, hyperpigmentation of the basal layer, and a mild superficial dermal lymphocytic infiltrate. Bullae may be either intraepidermal or subepidermal. Hyperplasia of the sebaceous glands with follicular dilatation and plugging may occur.[24, 25, 26]

Medical Care

Medical care is discussed as follows[3, 22, 25, 26, 33] :


Helpful consultations are as follows[3, 26, 33, 35] :


Advise patients who are symptomatic to consume a high-protein diet because it decreases the number of attacks.[3, 25, 36]


Advise patients to protect themselves from sunlight. Protective clothing, hats and eyewear, and physical and chemical sunscreens provide photoprotection.[26]


Deterrence and prevention are as follows[24, 25] :

Long-Term Monitoring

Advise patients to use protection from sunlight, to avoid other aggravating factors, to consume a high-protein diet, and to take daily supplements of nicotinic acid. In patients who are symptomatic, recommend regular follow-up examinations, depending on the severity of symptoms and the organ systems involved.

Medication Summary

Nicotinic acid or nicotinamide (50-300 mg/d) provides relief from both the skin manifestations and the neurologic manifestations.[3, 22, 36]

Administration of tryptophan ethyl ester (a lipid-soluble tryptophan metabolite) in a child with Hartnup disease at a dose of 20 mg/kg every 6 hours resulted in normalization of serum and cerebrospinal fluid tryptophan levels.[36]

Vitamin B-3 (Niacin, Nicotinic acid, Nicotinamide)

Clinical Context:  Nicotinamide is more commonly recommended. It is a source of niacin used in tissue respiration, lipid metabolism, and glycogenolysis. It provides relief from skin and neurologic manifestations.

Class Summary

Vitamins are necessary for normal growth and development. These agents are used to replace essential vitamins not obtained in sufficient quantities in the diet or to further supplement levels.


Lidija Kandolf Sekulovic, MD, PhD, Professor, Head of the Department of Dermatology and Venereology, Medical Faculty, Military Medical Academy, Belgrade, Serbia

Disclosure: Nothing to disclose.


Djordjije Karadaglic, MD, DSc, Professor, School of Medicine, University of Podgorica, Podgorica, Montenegro

Disclosure: Nothing to disclose.

Ljubomir Stojanov, MD, PhD, Lecturer in Metabolism and Clinical Genetics, University of Belgrade School of Medicine, Serbia

Disclosure: Nothing to disclose.

Specialty Editors

David F Butler, MD, Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

Disclosure: Nothing to disclose.

Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Pathology, Professor of Pediatrics, Professor of Medicine, Rutgers New Jersey Medical School

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD.


Mark A Crowe, MD Assistant Clinical Instructor, Department of Medicine, Division of Dermatology, University of Washington School of Medicine

Mark A Crowe, MD is a member of the following medical societies: American Academy of Dermatology and North American Clinical Dermatologic Society

Disclosure: Nothing to disclose.


  1. Baron DN, Dent CE, Harris H, Hart EW, Jepson JB. Hereditary pellagra-like skin rash with temporary cerebellar ataxia, constant renal amino-aciduria, and other bizarre biochemical features. Lancet. 1956 Sep 1. 271(6940):421-8. [View Abstract]
  2. Bröer S, Cavanaugh JA, Rasko JE. Neutral amino acid transport in epithelial cells and its malfunction in Hartnup disorder. Biochem Soc Trans. 2005 Feb. 33:233-6. [View Abstract]
  3. Galadari E, Hadi S, Sabarinathan K. Hartnup disease. Int J Dermatol. 1993 Dec. 32(12):904. [View Abstract]
  4. Bröer A, Cavanaugh JA, Rasko JE, Bröer S. The molecular basis of neutral aminoacidurias. Pflugers Arch. 2006 Jan. 451(4):511-7. [View Abstract]
  5. Seow HF, Broer S, Broer A, et al. Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19. Nat Genet. 2004 Sep. 36(9):1003-7. [View Abstract]
  6. Kleta R, Romeo E, Ristic Z, et al. Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder. Nat Genet. 2004 Sep. 36(9):999-1002. [View Abstract]
  7. Broer S, Cavanaugh JA, Rasko JE. Neutral amino acid transport in epithelial cells and its malfunction in Hartnup disorder. Biochem Soc Trans. 2005 Feb. 33:233-6. [View Abstract]
  8. Nozaki J, Dakeishi M, Ohura T, et al. Homozygosity mapping to chromosome 5p15 of a gene responsible for Hartnup disorder. Biochem Biophys Res Commun. 2001 Jun 8. 284(2):255-60. [View Abstract]
  9. Bröer A, Klingel K, Kowalczuk S, Rasko JE, Cavanaugh J, Broer S. Molecular cloning of mouse amino acid transport system B0, a neutral amino acid transporter related to Hartnup disorder. J Biol Chem. 2004 Jun 4. 279(23):24467-76. [View Abstract]
  10. Symula DJ, Shedlovsky A, Dove WF. Genetic mapping of hph2, a mutation affecting amino acid transport in the mouse. Mamm Genome. 1997 Feb. 8(2):98-101. [View Abstract]
  11. Bröer A, Juelich T, Vanslambrouck JM, Tietze N, Solomon PS, Holst J. Impaired Nutrient Signaling and Body Weight Control in a Na+ Neutral Amino Acid Cotransporter (Slc6a19)-deficient Mouse. J Biol Chem. 2011 Jul 29. 286(30):26638-51. [View Abstract]
  12. Seow HF, Broer S, Broer A, et al. Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19. Nat Genet. 2004 Sep. 36(9):1003-7. [View Abstract]
  13. Azmanov DN, Kowalczuk S, Rodgers H, et al. Further evidence for allelic heterogeneity in Hartnup disorder. Hum Mutat. 2008 Oct. 29(10):1217-21. [View Abstract]
  14. Zheng Y, Zhou C, Huang Y, Bu D, Zhu X, Jiang W. A novel missense mutation in the SLC6A19 gene in a Chinese family with Hartnup disorder. Int J Dermatol. 2009 Apr. 48(4):388-92. [View Abstract]
  15. Cheon CK, Lee BH, Ko JM, Kim HJ, Yoo HW. Novel mutation in SLC6A19 causing late-onset seizures in Hartnup disorder. Pediatr Neurol. 2010 May. 42(5):369-71. [View Abstract]
  16. Azmanov DN, Rodgers H, Auray-Blais C, et al. Persistence of the common Hartnup disease D173N allele in populations of European origin. Ann Hum Genet. 2007 Nov. 71:755-61. [View Abstract]
  17. Broer S. Apical transporters for neutral amino acids: physiology and pathophysiology. Physiology (Bethesda). 2008 Apr. 23:95-103. [View Abstract]
  18. Broer S. Apical transporters for neutral amino acids: physiology and pathophysiology. Physiology (Bethesda). 2008 Apr. 23:95-103. [View Abstract]
  19. Böhmer C, Sopjani M, Klaus F, Lindner R, Laufer J, Jeyaraj S, et al. The serum and glucocorticoid inducible kinases SGK1-3 stimulate the neutral amino acid transporter SLC6A19. Cell Physiol Biochem. 2010. 25(6):723-32. [View Abstract]
  20. Nässl AM, Rubio-Aliaga I, Fenselau H, Marth MK, Kottra G, Daniel H. Amino acid absorption and homeostasis in mice lacking the intestinal peptide transporter PEPT1. Am J Physiol Gastrointest Liver Physiol. 2011 Jul. 301(1):G128-37. [View Abstract]
  21. Milovanovic DD. A clinicobiochemical study of tryptophan and other plasma and urinary amino acids in the family with Hartnup disease. Adv Exp Med Biol. 2003. 527:325-35. [View Abstract]
  22. Schmidtke K, Endres W, Roscher A, et al. Hartnup syndrome, progressive encephalopathy and allo-albuminaemia. A clinico-pathological case study. Eur J Pediatr. 1992 Dec. 151(12):899-903. [View Abstract]
  23. Wilcken B, Yu JS, Brown DA. Natural history of Hartnup disease. Arch Dis Child. 1977 Jan. 52(1):38-40. [View Abstract]
  24. Oakley A, Wallace J. Hartnup disease presenting in an adult. Clin Exp Dermatol. 1994 Sep. 19(5):407-8. [View Abstract]
  25. Levy H. Hartnup Disorder. Scriver CR, Beaudet A L, Sly WS, Valle D. The metabolic and molecularbases of inherited disease. New York: McGraw-Hill; 2001. 4957-4969.
  26. Stojanov LJ, Karadaglic DJ. Skin changes in children with inborn errors of amino acids metabolism. Karadaglic DJ, ed. Dermatology. Belgrade: Vojnoizdavacki zavod-Verzal Press; 2000. 1505-12.
  27. Mahon BE, Levy HL. Maternal Hartnup disorder. Am J Med Genet. 1986 Jul. 24(3):513-8. [View Abstract]
  28. Scriver CR, Mahon B, Levy HL, et al. The Hartnup phenotype: Mendelian transport disorder, multifactorial disease. Am J Hum Genet. 1987 May. 40(5):401-12. [View Abstract]
  29. Seyhan ME, Selimoglu MA, Ertekin V, Fidanoglu O, Altinkaynak S. Acrodermatitis enteropathica-like eruptions in a child with Hartnup disease. Pediatr Dermatol. 2006 May-Jun. 23(3):262-5. [View Abstract]
  30. Orbak Z, Ertekin V, Selimoglu A, Yilmaz N, Tan H, Konak M. Hartnup disease masked by kwashiorkor. J Health Popul Nutr. 2010 Aug. 28(4):413-5. [View Abstract]
  31. Sander CS, Hertecant J, Abdulrazzaq YM, Berger TG. Severe exfoliative erythema of malnutrition in a child with coexisting coeliac and Hartnup's disease. Clin Exp Dermatol. 2009 Mar. 34(2):178-82. [View Abstract]
  32. Ciecierega T, Dweikat I, Awar M, Shahrour M, Libdeh BA, Sultan M. Severe persistent unremitting dermatitis, chronic diarrhea and hypoalbuminemia in a child; Hartnup disease in setting of celiac disease. BMC Pediatr. 2014 Dec 20. 14:311. [View Abstract]
  33. Camargo SM, Bockenhauer D, Kleta R. Aminoacidurias: Clinical and molecular aspects. Kidney Int. 2008 Apr. 73(8):918-25. [View Abstract]
  34. Henderson HE, Goodman R, Schram J, Diamond E, Daneel A. Biochemical screening for inherited metabolic disorders in the mentally retarded. S Afr Med J. 1981 Nov 7. 60(19):731-3. [View Abstract]
  35. Milovanovic D, Djukic A, Stepanovic R, Pekovic D, Vranjesevic D. [Hartnup disease (report of 2 cases in one family)]. Srp Arh Celok Lek. 2000 Mar-Apr. 128(3-4):97-103. [View Abstract]
  36. Jonas AJ, Butler IJ. Circumvention of defective neutral amino acid transport in Hartnup disease using tryptophan ethyl ester. J Clin Invest. 1989 Jul. 84(1):200-4. [View Abstract]

Photosensitivity with erythema, desquamation, and hypopigmentation and hyperpigmentation on the face.

Erythema and desquamation on the sun-exposed area of the right arm.

Photosensitivity with erythema, desquamation, and hypopigmentation and hyperpigmentation on the face.

Erythema and desquamation on the sun-exposed area of the right arm.